Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza

Translated title of the contribution: Fetal risks related to the administration of antiarrhythmic drugs during pregnancy

Simone Ferrero, Barbara M. Colombo, Elisa Arena, Fabio Fenini, Nicola Ragni

Research output: Contribution to journalArticle

Abstract

The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.

Original languageItalian
Pages (from-to)993-1002
Number of pages10
JournalItalian Heart Journal Supplement
Volume3
Issue number10
Publication statusPublished - Oct 2002

Fingerprint

Anti-Arrhythmia Agents
Fetal Development
Pregnancy
Mothers
Organogenesis
Growth and Development
Cardiac Arrhythmias
Milk
Nursing
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza. / Ferrero, Simone; Colombo, Barbara M.; Arena, Elisa; Fenini, Fabio; Ragni, Nicola.

In: Italian Heart Journal Supplement, Vol. 3, No. 10, 10.2002, p. 993-1002.

Research output: Contribution to journalArticle

Ferrero, S, Colombo, BM, Arena, E, Fenini, F & Ragni, N 2002, 'Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza', Italian Heart Journal Supplement, vol. 3, no. 10, pp. 993-1002.
Ferrero, Simone ; Colombo, Barbara M. ; Arena, Elisa ; Fenini, Fabio ; Ragni, Nicola. / Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza. In: Italian Heart Journal Supplement. 2002 ; Vol. 3, No. 10. pp. 993-1002.
@article{1a2ad425bb9148209289fca24383ca67,
title = "Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza",
abstract = "The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.",
keywords = "Arrhythmias supraventricular, Arrhythmias ventricular, Pregnancy",
author = "Simone Ferrero and Colombo, {Barbara M.} and Elisa Arena and Fabio Fenini and Nicola Ragni",
year = "2002",
month = "10",
language = "Italian",
volume = "3",
pages = "993--1002",
journal = "Italian Heart Journal Supplement",
issn = "1129-4728",
publisher = "Centro Editoriale Pubblicitario Italiano",
number = "10",

}

TY - JOUR

T1 - Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza

AU - Ferrero, Simone

AU - Colombo, Barbara M.

AU - Arena, Elisa

AU - Fenini, Fabio

AU - Ragni, Nicola

PY - 2002/10

Y1 - 2002/10

N2 - The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.

AB - The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.

KW - Arrhythmias supraventricular

KW - Arrhythmias ventricular

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=0242364179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242364179&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0242364179

VL - 3

SP - 993

EP - 1002

JO - Italian Heart Journal Supplement

JF - Italian Heart Journal Supplement

SN - 1129-4728

IS - 10

ER -